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Objective: To investigate the psychometric properties of the Clinical Dementia Scale—frontotemporal lo-
bar degeneration (CDR-FTLD) psychometric properties using Rasch analysis and its sensitivity
distinguishing disease progression between FTLD and Alzheimer’s disease (AD).
Methods: Of 603 consecutive patients from the National Alzheimer Coordinating Center dataset
(FTLD=350; AD=253), 120 FTLDs were included in a Rasch analysis to verify CDR-FTLD psychomet-
ric properties; 483 (FTLD=230; AD=253) were included to analyse disease progression, with 195
(FTLD=82; AD=113) followed-up (24months).
Results: The CDR-FTLD demonstrated good consistency, construct and concurrent validity and correlated
well with mini-mental state examination (MMSE) and disease duration (ps<0.05). At baseline, FTLD
showed greater dementia severity than AD after matched for MMSE and disease duration (p<0.001). Inde-
pendent Rasch analyses demonstrated different patterns of progression for FTLD and AD in terms of the
domains initially and then subsequently affected with disease progression. At follow-up, although MMSE
showed signiﬁcant changes (p<0.05), these were greater on the CDR-FTLD (p<0.001).
Conclusion: The CDR-FTLD satisfactorily measures dementia severity and change in FTLD,
distinguishing disease progression between FTLD and AD, with clear implications for care, prognosis
and future clinical trials. # 2016 The Authors. International Journal of Geriatric Psychiatry published
by John Wiley & Sons, Ltd.
Key words: frontotemporal dementia; frontotemporal lobar degeneration; disease progression; CDR-FTLD; dementia severity
History: Received 11 December 2015; Revised 15 June 2016; Accepted 20 June 2016; Published online in Wiley Online Library
(wileyonlinelibrary.com)
DOI: 10.1002/gps.4556
Introduction
The ability to detect clinical change and attribution of
accurate disease severity in frontotemporal lobar de-
generation (FTLD) is critical for appropriate charac-
terization of research cohorts, prognosis, clinical
management and future trials. In the spectrum of clin-
ical disorders due to Alzheimer’s disease (AD), the
Clinical Dementia Rating Scale (CDR) (Morris,
1993) is widely regarded as an excellent instrument
for rating severity. It is extensively used in drug trials
and research studies (Schneider et al., 1997; Rattinger
et al., 2015). Speciﬁc dementia staging tools in FTLD
have not achieved the same kind of consensus. The
Frontotemporal Dementia Rating Scale was published
in 2010 (Mioshi et al., 2010), demonstrating ability to
detect differences in disease progression in
frontotemporal dementia (FTD) subtypes and over
time. As such, speciﬁc tools such as the CDR or
Frontotemporal Dementia Rating Scale have demon-
strated capability to detect clinical change in different
dementia subtypes, but tools that can be reliably
applied in both disease groups are limited.
The Clinical Dementia Rating - FTLD scale-modiﬁed
(CDR-FTLD) (Knopman et al., 2008) addresses this
issue with the addition of two extra domains, language
and behaviour, making it more sensitive to FTLD
subtypes, while enhancing description of disease
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progression in the AD spectrum. It has been shown
ability to detect signiﬁcant change in FTLD-simulated
trials, but its applicability in AD clinical trials has not
been tested yet.
Here, we applied Rasch modelling to understand
the performance of the CDR-FTLD. Rasch analysis is
a powerful methodology based on item-response the-
ory, able to investigate items from a scale concomi-
tantly with the performance of patients in these same
items, allowing for a direct comparison. Patients and
items can be placed in the same continuum, providing
great insight into patient performance as well as item
difﬁculty, making this method very appropriate for
the validation of disease progression assessment tools.
This study aimed to (i) verify psychometric proper-
ties of the CDR-FTLD via Rasch analysis; (ii) investi-
gate if the CDR-FTLD could reveal different patterns
of disease progression between FTLD and AD demen-
tia; and (3) examine if the CDR-FTLD could detect
longitudinal changes in FTLD and AD dementia.
Methods
Participants
The National Alzheimer Coordinating Center
(NACC) developed a database containing extensive
clinical information on participants from 34 past and
present Alzheimer’s Disease Centres (ADCs) in the
USA. The NACC database was interrogated on 2 No-
vember 2012 to identify patients diagnosed with FTLD
or AD according to international criteria. The dataset
contained 11902 patients who were assessed between
September 2005 and August 2012. Of those, 603
patients were consecutively included if fulﬁlling the
following criteria: for FTLD (Neary et al., 1998;
Gorno-Tempini et al., 2011; Rascovsky et al., 2011)
(n=350), diagnosis of behavioural variant FTD,
primary progressive aphasia semantic variant or non-
ﬂuent variant and no concurrent diagnosis of progres-
sive supranuclear palsy, corticobasal degeneration,
depression or other psychiatric disease at their ﬁrst
visit, as recorded in the NACC database. Inclusion
criteria for dementia due to AD (n=253) were diagno-
sis of possible or probable AD (McKhann et al., 2011)
and no concurrent diagnosis of vascular dementia,
dementia with Lewy bodies, depression or other psychi-
atric disease at the ﬁrst visit. The NACC protocol and
diagnostic criteria have been extensively published.
Participants were consecutively included to the
FTLD test sample 1 (n=120), the FTLD replication
sample 2 (n=230) or the AD dementia replication
sample 3 (n=253). Of the replication sample, 82/230
patients with FTLD had 1–3 follow-up visits; 113/253
patients with AD dementia had follow-up data
(Figure 1). Follow-up data were taken from the visit
that took place approximately 24months following
baseline.
Instruments
Clinical Dementia Rating Scale for FTLD. The CDR-
FTLD is an extended version of the CDR and includes
two additional domains: language and behaviour. It
has shown to be more sensitive to FTLD than the orig-
inal CDR, where it was 27% more sensitive in detect-
ing decline over 12months than the standard CDR
score (Knopman et al., 2011). The ‘sum of boxes’, that
is, the sum of the individual domain ratings, was used
to determine global dementia severity.
General cognitive assessment. The mini-mental state
examination (MMSE) (Folstein et al., 1975) was used
at baseline and follow-up visits. The MMSE is a global
cognitive assessment widely used in clinical and re-
search dementia centres. The maximum score is 30,
with two cut-offs: 24 (sensitivity 66%, speciﬁcity
99%) and 27 (sensitivity 89%, speciﬁcity 91%) indica-
tive of cognitive decline yielding different rates of sen-
sitivity and speciﬁcity for dementia (O’Bryant et al.,
2008).
Statistical analyses
For the investigation of the psychometric properties of
the CDR-FTLD and its validation, a number of met-
rics were generated by a Rasch analysis (Sample 1) to
verify scale item suitability, internal validity and unidi-
mensionality. Rasch analysis allows for the simulta-
neous veriﬁcation of the ranking of items in a scale
(very difﬁcult to easy), while concomitantly ranking
all patients in order of ability (less severe to more se-
vere). Concurrent validity of the scale was checked
against the MMSE and length of symptoms, using
IBM SPSS 20. The Rasch analyses steps were analysed
using Winsteps 7.
For the investigation of the clinical change in FTLD
and AD dementia, another two independent Rasch
analyses were conducted, one with each diagnostic
subgroup (Samples 2 and 3), which revealed the clin-
ical progression of each dementia subtype. Given the
violation of normality in the distribution of the
CDR-FTLD scores for both FTLD and AD dementia,
non-parametric repeated measures Wilcoxon test was
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applied in a subset of patients with follow-up visits
(average 24months) to verify the ability of the scale
in detecting change over time. Non-parametric
Spearman rank correlation analyses were also
performed between the CDR-FTLD and the MMSE
and length of symptoms.
Results
Patient characteristics
The FTLD and AD groups were well matched for the
time of disease duration (Table 1). The proportion of
men and women was dissimilar in both groups, which
had also different rates of married people, but mostly
had English as their ﬁrst language. General cognitive
scores were matched for FTLD and AD dementia,
but severity of dementia was greater for FTLD, as de-
ﬁned by the CDR-FTLD ‘sum of boxes’.
Validation of the CDR-FTLD: psychometric properties
(Sample 1)
The CDR-FTLD fulﬁls all criteria for a valid scale. In
regard to items (construct validity), the mean square
inﬁt [M=1.12 (SD=0.76), Z=0.5 (SD=3.9)] and
outﬁt [M=1.26 (SD=0.94), Z=0 (SD=3.7)] were
within the desired values (0.60–1.49; Z=2 to 2).
Unidimensionality was low (29%; desired raw
variance would be 50%) because the scale is inher-
ently not unidimensional: It contains different
dimensions such as memory, language and behav-
iour. Test consistency was excellent (0.93), very close
to Cronbach’s alpha of 0.95 (Bland and Altman,
1997). Item separation was 3.78, which is also very
close to the desired value of 3.0 (Linacre and Wright,
2000) (Table 2).
Concurrent validity of the CDR-FTLD was con-
ﬁrmed by correlations with the MMSE: There was a
signiﬁcant correlation for both patients with FTLD
(r=0.591, p<0.001) and patients with AD
(r=0.778, p<0.001). There were also signiﬁcant
correlations between the CDR-FTLD and length of
symptoms for both disease groups (FTLD: r=0.348,
p<0.001) and AD dementia: r=0.386, p<0.001).
Is clinical change in FTLD different from AD?
Two independent Rasch analyses (Samples 2 and 3,
Figure 1) were conducted for the investigation of
clinical change in FTLD and AD using the CDR-
Table 1 Demographic and clinical characteristics of patients with FTLD and AD at baseline (Samples 2 and 3). Means; SD in brackets
FTLD (n = 230) AD dementia (n = 253) FTLD versus AD dementia
Age, years 63.9 (8.97) 74.8 (10.0) *p< 0.001
Disease duration, years 4.8 (3.5) 4.4 (3.0) *p = 0.169
Male, % 57.6 44.7 **p< 0.001
Primary language, English % 91.7 91.7 **n.s.
Marital status, married % 78.6 66.4 **p< 0.001
MMSE (max 30) 21.7 (7.5) 22.4 (12.5) *p = 0.089
CDR-FTLD sum of boxes (max 24) 8.4 (5.8) 4.7 (3.7) *p< 0.001
*t-test, p> 0.05.
**Chi-square, p< 0.05.
Figure 1 Schematic representation of data samples used in the study.
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FTLD items. In this analysis, the CDR-FTLD items
were ranked according to the higher assignment of
severity exhibited by the patient sample, in this case,
each diagnostic group. Figure 2 shows that items with
high values are areas affected very early in the disease
course, while low value items referring to domains
preserved until late in the disease course.
As such, the patients with FTLD showed early
susceptibility to impairment in judgement and prob-
lem solving; next, it was behaviour, comportment
and personality and community affairs (Figure 2).
Language, memory and orientation were affected later
on, and the last domain to be affected was personal
care.
For the patients with AD dementia, the expected
proﬁle of clinical change was distinct from that of
FTLD. Memory was by far the most susceptible do-
main to be affected, followed by community affairs,
judgement and problem solving, orientation and
home and hobbies. Language and behaviour were only
affected much later in the clinical course, together
with personal care.
Clinical decline at follow-up
At baseline, both groups were matched for MMSE
scores and length of symptoms, but the CDR-FTLD
scores were clearly distinct (FTLD>AD dementia,
p<0.001). At follow-up (average 24months), the
CDR-FTLD sum of boxes (max 24) were signiﬁcantly
lower for both FTLD and AD (both ps<0.001),
reﬂecting sensitivity to change over time (Figure 3).
Discussion
This study systematically investigated patterns of dis-
ease progression in FTLD and AD at different stages
with a well-validated staging measure. The results
Table 2 Demographic and clinical characteristics of patients with FTLD and AD at follow-up (Sample 3). Means; SD in brackets
FTLD (n = 82) AD dementia (n = 113) FTLD versus AD dementia
Age, years 66.6 (9.4) 78.3 (9.2) *p< 0.001
Disease duration, years 6.8 (3.0) 7.1 (3.6) *p = 0.541
Male, % 57.8 55.8 **p = 0.772
Primary language, English % 88.0 90.3 **p = 0.139
Marital status, married % 77.1 62.8 **p< 0.05
MMSE (max 30) 22.34 (7.2) 22.5 (5.6) *p = 0.763
CDR FTLD sum boxes (max 24) 8.3 (5.3) 5.0 (3.8) *p = 0.001
Time between baseline and follow-up visit (months) 22.1 (1.0) 26.3 (11.7) *p = 0.01
*t-test, p> 0.05.
**Chi-square, p< 0.05.
Figure 2 Distribution of Clinical Dementia Scale—frontotemporal lobar degeneration items for (A) patients with frontotemporal lobar degeneration
TLD and (B) Alzheimer’s disease. Higher logit scores represent greater severity.
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conﬁrm that the CDR-FTLD provided a clear distinc-
tion of clinical changes in the two dementia subtypes,
with evident implications for clinical management
and future trials of pharmacological and non-
pharmacological interventions.
The CDR-FTLD can detect clinical change in FTLD
and satisﬁes required psychometric properties in a
number of parameters. Item suitability and item separa-
tion were conﬁrmed, with test consistency considered
excellent. The measure was strongly associated with
global cognitive changes, as measured by the MMSE
and length of symptoms, while demonstrating a distinct
clinical pattern of progression difference between FTLD
and AD dementia. This study went beyond prior analy-
ses (Knopman et al., 2011) and conﬁrmed the utility of
the CDR-FTLD in detecting changes in FTLD and AD
dementia over time using Rasch analysis.
The application of Rasch modelling in the process
of validating scales is very robust (Bond and Fox,
2015), given its roots in item-response theory. Item-
response theory models the relationship between abil-
ities measured (e.g. domains in dementia progression)
and responses (e.g. patients’ performance in the scale)
in a mathematical way. In this way, items and respon-
dents are placed in the same dimension and can be
compared directly. Traditional approaches in validat-
ing health scales tend to rely on classic test theory,
which relies on correlations and may be limited in its
applicability when tests adopt Likert scales (Churchill,
1979), such as the CDR-FTLD.
Another advantage of Rasch analysis in validating
assessments lies in its strength to determine the most
important aspect of test validity, namely construct
validity (Wampold, 1998). Construct validity refers
to the ability of the scale in measuring things hierar-
chically, which in the case of the CDR-FTLD, ﬁts
seamlessly in conﬁrming disease progression in FTLD.
The validation Rasch results demonstrated that the
items of the CDR-FTLD can effectively order well a
patient sample in a disease continuum, from very mild
to very severe. Importantly, the replication sample not
only conﬁrmed the test applicability in FTLD but also
in an independent sample of AD dementia.
By examining the clinical changes in FTLD in a data-
driven approach such as Rasch analysis, our results can
guide future interventions to clear targets of disease-
modifying therapies (as well as non-pharmacological
approaches) at different dementia stages.
The limitations in this study include the merging of
FTLD subtypes, and for this reason, the differences in
variants could not be investigated here. We also lacked
autopsy conﬁrmation in both FTLD and AD dementia
subgroups, but as with most published studies, we re-
lied on clinical diagnoses made by expert clinicians in
the US Alzheimer centres. The strengths of our study
include the Rasch analysis methodology for the valida-
tion of the CDR-FTLD in FTLD, large clinical sam-
ples, as well as validation in independent cohorts of
patients with FTLD and AD, which have also contrib-
uted to a greater understanding of the variances in
disease progression in the two dementia subtypes.
The understanding of differences in the course of
dementia subtypes and validation of appropriate mea-
sures not only inform future trials and clinical
research, but it can also provide clinical teams with
an instrument that can objectively measure relevant
health and social care needs at different stages of FTLD.
Key points
• The CDR-FTLD satisfactorily measures
dementia severity and change in FTLD,
distinguishing disease progression between
FTLD and AD, with clear implications for
care, prognosis and future clinical trials.
Figure 3 (A) Baseline scores; (B) Follow up scores Distribution of CDR-FTLD sum of boxes severity for FTLD and AD at (A) baseline and
(B) follow up.
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